"I Have Never Seen a Moment So Rich in Collaboration, Ingenuity and Acts of Bravery": Johnson & Johnson Announces It Has Identified a Lead COVID-19 Vaccine Candidate
Johnson & Johnson Joins Other Companies in Signing a Landmark Communiqué on Expanded Global Access for COVID-19Did you enjoy reading this story? Click the heart.
Did you like taking this quiz? Click the heart to show your love.
Have Questions About Participating in a COVID-19 Vaccine Clinical Trial? A Doctor Overseeing a Study Helps Answer ThemDid you like reading this story? Click the heart to show your love.
he COVID-19 pandemic is one of the greatest challenges to our society in living memory.
Yet even as we are heartbroken by the lives lost and the strain on our institutions and communities, countless people have been working tirelessly to offer the world a reason to feel pride, inspiration and hope.
In my 31 years working in healthcare, I have never seen a moment so rich in collaboration, ingenuity and acts of bravery. Public health authorities, private sector companies, research universities, governments and, most of all, the heroes on the front lines of care are mobilizing in ways that current generations have never before witnessed.
In 1918, Johnson & Johnson supported the doctors and nurses treating Spanish influenza through scientific innovation, just as we are now deploying the full strength of our company against this new pandemic.
And as a result of focused efforts and extensive collaboration underway since January, today we are able to announce that Johnson & Johnson has selected a lead Covid-19 vaccine candidate. We expect to initiate human clinical studies by September 2020, and anticipate that the first batches of a COVID-19 vaccine could be available for emergency-use authorization in early 2021—a substantially accelerated time frame in comparison to the typical vaccine development process.
We consider this one of the most pivotal moments in our 134-year history. Johnson & Johnson is committed to doing our part to make a COVID-19 vaccine available and affordable as quickly as possible.ShareDid you like reading this story? Click the heart to show your love.
Through a landmark new partnership, the Biomedical Advanced Research and Development Association (BARDA) and Johnson & Johnson together have committed more than $1 billion of investment to co-fund vaccine research, development and clinical testing—and to expand our company’s global manufacturing capacity to enable the supply of more than 1 billion doses of a safe and effective vaccine to the public for emergency pandemic use on a not-for-profit basis.
We consider this one of the most pivotal moments in our 134-year history. Johnson & Johnson is the largest healthcare company in the world. And because of the scale of our global reach and the depth of our expertise, we are committed to doing our part to make a COVID-19 vaccine available and affordable as quickly as possible.
As people in every country and walk of life are being tested in new ways, we are discovering that we are capable of more than we could have dreamed of just weeks ago. And what fills me with the most hope right now is the immense courage of all who are taking on the duty of caring for their communities.
Frontline care workers and doctors rushing to treat patients with the disease. Researchers working tirelessly behind the scenes. Manufacturing employees going above and beyond to keep production lines running. Families and neighbors supporting each other in ordinary and extraordinary ways.
This is a time when our strength as a society is being tested—and proven.